Agenus Inc. (AGEN) is advancing its lead immuno-oncology program, BOT+BAL, in a Phase III study for refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC). The BATTMAN study aims to address a significant unmet need, particularly in a difficult-to-treat patient population, but the company faces a considerable financing overhang that may impact its strategy and execution timelines.
As of March 31, 2026, Agenus reported $35 million in cash and marketable securities, a notable increase from $3 million the previous quarter. However, it also carries $30 million in debt, primarily short-term. In Q1 2026, Agenus’ revenue reached $33.7 million, though this fell short of the $129.5 million consensus estimate, largely due to $29.1 million in non-cash royalty revenue.
Agenus has secured $91 million in upfront capital through a collaboration with Zydus Lifesciences, aimed at bolstering its liquidity. However, a recent SEC filing included a going-concern disclosure related to its ongoing capital needs to fund operations and advance BOT+BAL, raising concerns about its financial stability in the near term.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
